ACM
SAGE

AlphaCrest Capital Management’s Sage Therapeutics SAGE Stock Holding History

AlphaCrest Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5,772
Closed -$328K – 1364
2021
Q2 		$328K Buy
5,772
+2,630
+84% +$186K 0.01% 1083
2021
Q1 		$235K Buy
+3,142
New +$258K 0.01% 1091
2019
Q4 		– Sell
-1,800
Closed -$253K – 1355
2019
Q3 		$253K Buy
+1,800
New +$301K 0.02% 1147

Other funds holding SAGE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

AlphaCrest Capital Management's SAGE Position: Q3 2021 in Review

AlphaCrest Capital Management sold out of Sage Therapeutics (SAGE) in Q3 2021, closing a stake of 5,772 shares — an estimated $328K sold.

AlphaCrest Capital Management first reported a position in SAGE in Q3 2019 and held it in 3 quarters. The position peaked at $328K in Q2 2021. 225 funds tracked by Wall St. Rank hold SAGE as of Q3 2021.

  • AlphaCrest Capital Management reported no remaining Sage Therapeutics position as of Q3 2021 after selling out during the quarter.
  • AlphaCrest Capital Management sold 5,772 Sage Therapeutics shares in Q3 2021, an estimated $328K.
  • AlphaCrest Capital Management first reported a position in Sage Therapeutics in Q3 2019 and held it in 3 quarters.
  • AlphaCrest Capital Management's Sage Therapeutics position peaked at $328K in Q2 2021.
  • 225 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2021.

Based on AlphaCrest Capital Management's 13F filing for Q3 2021, filed 10 Nov 2021.